Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Jinhui Dong(Vanderbilt University Medical Center), James E. Crowe(Vanderbilt University Medical Center), Robert H. Carnahan(Vanderbilt University Medical Center), Rachel E. Sutton(Vanderbilt University Medical Center), Kevin M. Tuffy(Penn State Milton S. Hershey Medical Center), Christopher Gainza(Vanderbilt University Medical Center), Stuart Weston(University of Maryland, Baltimore), Tyler Brady(National Institutes of Health), Matthew B. Frieman(University of Maryland, Baltimore), Pavlo Gilchuk(AstraZeneca (Japan)), James Brett Case(Washington University in St. Louis), Rachel S. Nargi(Vanderbilt University Medical Center), James Logue(National Institutes of Health), Elad Binshtein, Adam S. Dingens(Fred Hutch Cancer Center), Rita E. Chen(Washington University in St. Louis), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Jessica Rodríguez(Vanderbilt University Medical Center), Erica Armstrong(Vanderbilt University Medical Center), Yueh–Ming Loo(Intego (Germany)), Michael Diamond(Washington University in St. Louis), Elaine C. Chen(Vanderbilt University Medical Center), Marisa E. McGrath(University of Maryland, Baltimore), Allison J. Greaney(University of Washington), Seth J. Zost(Vanderbilt University Medical Center), Mark T. Esser(AstraZeneca (United States)), Jesse D. Bloom(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Helen Bright(AstraZeneca (United States)), Patrick M. McTamney(AstraZeneca (United States)), Tyler N. Starr(University of Utah), Xianwen Zhang(Hunan Agricultural University), Xuping Xie(The University of Texas Medical Branch at Galveston)
Cited by 331
Related Papers
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k